BYE-LAWS IN TERMS OF THE GENERAL REGULATIONS FOR UNIVERSITY POSTGRADUATE AWARDS, 2021 FOR THE DEGREE OF MASTER OF

PHARMACOTOXICOLOGY - M.SC.

SUBSIDIARY LEGISLATION 327.667

BYE-LAWS IN TERMS OF THE GENERAL

REGULATIONS FOR UNIVERSITY POSTGRADUATE

AWARDS, 2021 FOR THE DEGREE OF MASTER OF

SCIENCE IN PHARMACOTOXICOLOGY - M.SC. -

UNDER THE AUSPICES OF THE FACULTY OF

MEDICINE AND SURGERY

7th September 2021

LEGAL NOTICE 351 of 2021.

(1) These bye-laws may be cited as the Bye-Laws in terms

of the General Regulations for University Postgraduate Awards,

2021 for the Degree of Master of Science in Pharmacotoxicology -

M.Sc. - under the auspices of the Faculty of Medicine and Surgery.

(2)

In these bye-laws, unless the context otherwise requires -

“the Board” means the Board of the Faculty of Medicine and

Surgery;

“the Board of Studies” means the Board of Studies appointed by

Senate for the Course on the recommendation of the Board;

“the Course” means the programme of study leading to the

degree of Master of Science in Pharmacotoxicology - M.Sc.;

“the Degree” means the degree of Master of Science in

Pharmacotoxicology - M.Sc. ;

“the Postgraduate Certificate” means the Postgraduate

Certificate in Pharmacotoxicology - P.G. Cert.;

“the Postgraduate Diploma” means the Postgraduate Diploma in

Pharmacotoxicology - P.G. Dip.; and

“the Principal Regulations” means the General Regulations for

University Postgraduate Awards, 2021.

These bye-laws shall be applicable for courses

commencing in October 2021 or later.

(1) The Course shall be open to applicants in possession of

(a)

the degree of Doctor of Medicine and Surgery; or

(b)

the degree of Master of Dental Surgery, (or the

degree of Bachelor of Dental Surgery obtained with

at least Second Class Honours if awarded prior to

July 2018); or

(c)

the degree of Master of Pharmacy, (or the degree of

Bachelor of Pharmacy (Honours) obtained with at

least Second Class Honours if awarded prior to July

2012); or

PHARMACOTOXICOLOGY - M.SC.

(d)

an Allied Health Sciences degree which includes a

pharmacology component, obtained with at least

Second Class Honours; or

(e)

a Bachelor’s degree in Medical Biochemistry,

Pharmaceutical Science, Pharmacology, or any

other area of study which includes a pharmacology

component and is deemed suitable by the Board of

Studies, obtained with at least Second Class

Honours or Category II.

(2) The Board shall recommend to Senate the number of

a p p l i c a n t s t h at m a y b e a l l o w e d t o r e g i st e r f o r t h e C o u r s e ,

depending on the availability of resources. The Board shall

announce the number of available places at the time of the call for

applications.

(3) When the number of places is so limited and the number of

eligible applicants exceeds the number of places available,

applicants shall be selected using the following criteria, the

weighting of which shall be published at the time of the call for

applications

(a)

degree class;

(b)

experience in the area of the proposed study; and

(c)

performance during an interview, if deemed

necessary.

(4) Interviews, if necessary, shall be conducted by a board

composed of at least three members appointed for the purpose by

the Board.

(5) For the purpose of selection, applicants who fully satisfy

the entry requirements by 31st August preceding the

commencement of the Course shall be considered first.

(1) Il-Kors ikun miftuħ għall-applikanti li għandhom

(a)

il-grad ta’ Doctor of Medicine and Surgery; jew

PHARMACOTOXICOLOGY – M.SC.

(b)

il-grad ta’ Master of Dental Surgery, (jew il-grad

ta’ Bachelor of Dental Surgery miksub mill-anqas

fit-Tieni Klassi bl-Unuri jekk mogħti qabel Lulju

tal-2018); jew

(ċ)

il-grad ta’ Master of Pharmacy, (jew il-grad ta’

Bachelor Pharmacy (Honours) miksub mill-anqas

fit-Tieni Klassi bl-Unuri jekk mogħti qabel Lulju

tal-2012); jew

(d)

grad f’suġġett relatat max-Xjenzi tas-Saħħa li

jinkludi komponent farmakoloġiku, miksub mill-

anqas fit-Tieni Klassi bl-Unuri; jew

(e)

grad ta’ Bachelor fil-Medical Biochemistry jew fil-

Pharmaceutical Science jew fil-Pharmacology jew

fi kwalunkwe qasam ta’ studju ieħor li jinkludi

komponent ta’ farmakoloġija u li jkun meqjus

xieraq mill-Bord tal-Istudji, miksub mill-anqas fit-

Tieni Klassi bl-Unuri jew f’Kategorija II.

(2) Il-Bord għandu jirrakomanda lis-Senat l-għadd ta’ applikanti

li jistgħu jitħallew jirreġistraw għall-Kors, skont id-disponibbiltà tar-

riżorsi. Il-Bord għandu jħabbar l-għadd ta’ postijiet disponibbli fiż-

żmien tas-sejħa għall-applikazzjonijiet.

(3) Meta l-għadd ta’ postijiet jkun limitat u l-għadd ta’ applikanti

eliġibbli jaqbeż l-għadd ta’ postijiet disponibbli, l-applikanti

jintgħażlu skont il-kriterji li ġejjin, bil-piż għal kull wieħed ikun

ippubblikat fiż-żmien tas-sejħa tal-applikazzjonijiet

(a)

il-klassifikazzjoni tal-grad;

(b)

l-esperjenza fil-qasam tal-istudju propost; u

(ċ)

il-livell milħuq matul intervista, jekk meqjusa

neċessarja.

(4) L-intervisti, jekk neċessarji, għandhom ikunu mmexxija

minn bord magħmul mill-anqas minn tliet membri maħtura għal dan

il-għan mill-Bord.

(5) Għall-għan tal-għażla, l-applikanti li jissodisfaw ir-rekwiżiti

kollha għad-dħul fil-Kors sal-31 ta’ Awwissu ta’ qabel ma jibda l-

Kors għandhom jitqiesu l-ewwel.

The Course shall extend over two or three years of part-

time study.

The programme of study shall comprise study-units to

which a total of 90 ECTS credits are assigned, of which 60 ECTS

credits are assigned to taught study-units and 30 ECTS credits are

assigned to the dissertation study-unit.

Students who successfully complete a prescribed set of

study-units totalling 30 ECTS credits for taught study-units with an

average mark of at least 50% and do not proceed with the Course,

or having proceeded do not successfully complete the Course, shall

be eligible for the award of the Postgraduate Certificate.

Students who obtain the 60 ECTS credits assigned to the

taught study- units with an average mark of at least 50% and do not

proceed with the Course, or having proceeded do not successfully

complete the dissertation, shall be eligible for the award of the

PHARMACOTOXICOLOGY - M.SC.

Postgraduate Diploma.

Students shall be eligible for the award of the Degree if

they obtain the 90 ECTS credits as outlined in the programme of

study for the Course with an average mark of at least 50%.

The programme of study shall be published after approval

by Senate, normally not less than eight months prior to the

commencement of the Course.

(1)The assessment of each taught study-unit shall be

completed by the end of the semester in which the teaching of the

study-unit is held.

(2) Students who in any academic year fail in the assessment

of not more than 10 ECTS credits shall be given the opportunity to

re-sit the failed assessments during the September assessment

session.

(3) Students who fail in more than the number of credits

permitted under paragraph (2) of this bye-law or students who after

re-assessment fail to obtain credit for any study-unit shall be

required to withdraw from the Course.

(1) Students shall be required to submit an individual

dissertation of approximately 15,000 to 20,000 words in

accordance with the guidelines issued by the Board of Studies.

(2) Work on the dissertation shall be undertaken during the

final two semesters of the Course; provided that students wishing to

complete the Course over two calendar years shall be allowed to

work on the dissertation during the two summer periods following

the taught semesters. Such students will be required to inform the

Board of Studies of this decision by not later than the first semester

of the second year of the Course.

(3) A provisional title for the dissertation and a detailed

research proposal shall be submitted to the Board of Studies for

approval by the beginning of the third semester.

(1) Students shall be required to have regular contact with

their supervisor.

(2) Supervisors shall submit to the Board of Studies progress

reports for each student under their supervision at the end of each

semester of studies. Such reports may include recommendations to

either

(a) extend the period of study in order to enable the student to

complete the dissertation; or

(b) terminate studies prematurely if the supervisor deems this to

be proper in the circumstances, provided that

(i)

the extension of the study period referred to in (a)

shall be in accordance with the provisions of

Principal Regulations; and

(ii)

the Board may not terminate studies prematurely

according to (b) until it has first given the student a

PHARMACOTOXICOLOGY - M.SC.

chance to be heard.

The Final Weighted Average Mark for the purpose of the

classification of the Postgraduate Diploma and of the Degree shall

be based on the results obtained in all the components of the

programme of study, all credits being weighted equally.